Expansion of polyfunctional HIV-specific T cells upon stimulation with mRNA electroporated dendritic cells in the presence of immunomodulatory drugs

Journal of Virology

Volumn 86, Issue 17, 2012, Pages 9351-9360

  De Keersmaecker, Brenda ^a   Allard, Sabine D ^b   Lacor, Patrick ^b   Schots, Rik ^b   Thielemans, Kris ^a   Aerts, Joeri L ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAG PROTEIN; GAMMA INTERFERON; INTERLEUKIN 2; LENALIDOMIDE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; NEF PROTEIN; PERFORIN; POMALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTIGEN SENSITIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL PROLIFERATION; CELL STIMULATION; CELLULAR IMMUNITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; DENDRITIC CELL; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; ELECTROPORATION; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOMODULATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE POLYFUNCTIONALITY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DENDRITIC CELLS; ELECTROPORATION; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC FACTORS; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RNA, MESSENGER; SPECIES SPECIFICITY; THALIDOMIDE;

EID: 84866169745     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00472-12     Document Type: Article

References (51)

1. Allard SD, et al. 2012. A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev, and Nef expressing dendritic cells followed by treatment interruption. Clin. Immunol. 142:252-268.
2. Allard SD, et al. 2008. Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev, and Nef. Vaccine 26:3735-3741.
3. Almeida JR, et al. 2007. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 204:2473-2485.
4. Appay V, Douek DC, Price DA. 2008. CD8+ T cell efficacy in vaccination and disease. Nat. Med. 14:623-628.
5. Bariol C, et al. 2002. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J. Gastroenterol. Hepatol. 17:135-139.
6. Bekker LG, Haslett P, Maartens G, Steyn L, Kaplan G. 2000. Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis. J. Infect. Dis. 181:954-965.
7. Bennett MS, Ng HL, Dagarag M, Ali A, Yang OO. 2007. Epitopedependent avidity thresholds for cytotoxic T-lymphocyte clearance of virus-infected cells. J. Virol. 81:4973-4980.
8. Berger CT, et al. 2011. High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control. J. Virol. 85:9334-9345.
9. Betts MR, et al. 2006. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107:4781-4789.
10. Bibas M, et al. 2010. Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone. J. Clin. Oncol. 28: e704-e708.doi: 10.1200/JCO.2010.30.0038.
11. Brinchmann JE, et al. 1994. Expression of costimulatory molecule CD28 on T cells in human immunodeficiency virus type 1 infection: functional and clinical correlations. J. Infect. Dis. 169:730-738.
12. Cafaro A, Macchia I, Maggiorella MT, Titti F, Ensoli B. 2009. Innovative approaches to develop prophylactic and therapeutic vaccines against HIV/AIDS. Adv. Exp. Med. Biol. 655:189-242.
13. Chang DH, et al. 2006. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 108:618-621.
14. Chen N, et al. 2007. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J. Clin. Pharmacol. 47:1466-1475.
15. Corral LG, et al. 1999. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J. Immunol. 163:380-386.
16. Corral LG, et al. 1996. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol. Med. 2:506-515.
17. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. 1994. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 91:4082-4085.
18. Darrah PA, et al. 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13:843-850.
19. Davies FE, et al. 2001. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98:210-216.
20. De Keersmaecker B, et al. 2011. The combination of 4-1BBL and CD40L strongly enhances the capacity of dendritic cells to stimulate HIV-specific T cell responses. J. Leukoc. Biol. 89:989-999.
21. Dredge K, et al. 2002. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J. Immunol. 168:4914-4919.
22. Ganusov VV, et al. 2011. Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection. J. Virol. 85:10518-10528.
23. García F, et al. 2011. A therapeutic dendritic cell-based vaccine for HIV-1 infection. J. Infect. Dis. 203:473-478.
24. García F, et al. 2005. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J. Infect. Dis. 191:1680-1685.
25. García F, Routy JP. 2011. Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection. Workshop in dendritic cell-based vaccine clinical trials in HIV-1. Vaccine 29:6454-6463.
26. Hanekom WA, et al. 2001. The immunomodulatory effects of thalidomide on human immunodeficiency virus-infected children. J. Infect. Dis. 184:1192-1196.
27. Haslett PA, Hanekom WA, Muller G, Kaplan G. 2003. Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J. Infect. Dis. 187:946-955.
28. Haslett PA, et al. 1999. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res. Hum. Retrovir. 15:1169-1179.
29. Hsu AK, et al. 2011. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 117:1605-1613.
30. Jacobson JM, et al. 1997. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N. Engl. J. Med. 336:1487-1493.
31. Julg B, et al. 2010. Enhanced anti-HIV functional activity associated with Gag-specific CD8 T-cell responses. J. Virol. 84:5540-5549.
32. Kaplan G, et al. 2000. Thalidomide for the treatment of AIDS-associated wasting. AIDS Res. Hum. Retrovir. 16:1345-1355.
33. Kiepiela P, et al. 2007. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13:46-53.
34. Kotla V, et al. 2009. Mechanism of action of lenalidomide in hematological malignancies. J. Hematol. Oncol. 2: 36.
35. LeBlanc R, et al. 2004. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 103:1787-1790.
36. Levy L, Fasal P, Levan NE, Freedman RI. 1973. Treatment of erythema nodosum leprosum with thalidomide. Lancet ii: 324-325.
37. Lu W, Arraes LC, Ferreira WT, Andrieu JM. 2004. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat. Med. 10:1359-1365.
38. Martinez V, et al. 2011. Lenalidomide in treating AIDS-related Kaposi's sarcoma. AIDS 25:878-880.
39. McNeil AC, et al. 2001. High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 98:13878-13883.
40. Michiels A, et al. 2005. Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. Gene Ther. 12:772-782.
41. Neuber B, et al. 2011. Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma. J. Immunol. 187:1047-1056.
42. Noonan K, et al. 2012. Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. Clin. Cancer Res. 18:1426-1434.
43. Pereyra F, et al. 2008. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J. Infect. Dis. 197:563-571.
44. Quach H, et al. 2010. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 24:22-32.
45. Routy JP, et al. 2010. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin. Immunol. 134:140-147.
46. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. 1991. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. 173:699-703.
47. Speiser DE, Kyburz D, Stübi U, Hengartner H, Zinkernagel RM. 1992. Discrepancy between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities. Low T cell receptor specificity and avidity sufficient for in vitro proliferation or cytotoxicity to peptide-coated target cells but not for in vivo protection. J. Immunol. 149:972-980.
48. Speiser DE, et al. 1999. CD28-negative cytolytic effector T cells frequently expressNKreceptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. Eur. J. Immunol. 29:1990-1999.
49. Tuyaerts S, et al. 2003. Induction of Influenza Matrix Protein 1 and Melan A-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells. Cancer Gene Ther. 10:696-706.
50. Van Gulck ER, et al. 2006. Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins. Blood 107:1818-1827.
51. Yadav A, et al. 2006. HIV-1 transgenic rat CD4+ T cells develop decreased CD28 responsiveness and suboptimal Lck tyrosine dephosphorylation following activation. Virology 353:357-365.